16.09.2021 23:26:24
|
FDA Expands EUA For Lilly's Bamlanivimab, Etesevimab To Include Post-exposure Prophylaxis For COVID
(RTTNews) - Eli Lilly and Company (LLY) Thursday said that the U.S. Food and Drug Administration has expanded the Emergency Use Authorization for bamlanivimab and etesevimab administered together to include post-exposure prophylaxis in certain individuals for the prevention of SARS-CoV-2 infection.
The neutralizing antibodies can now be used together to treat high-risk individuals 12 years of age and older who have not been fully vaccinated against COVID-19 or are not expected to mount an adequate immune response to complete vaccination, and have been exposed to someone infected with SARS-CoV-2 or who are at high risk of exposure in an institutional setting, including a nursing home or prison.
The expanded authorization is based on data from BLAZE-2 that enrolled residents and staff at long-term care facilities, across the U.S. In this placebo-controlled Phase 3 study, bamlanivimab reduced the risk of contracting symptomatic COVID-19 by up to 80 percent in nursing home residents and up to 57 percent among residents and staff of long-term care facilities.
BLAZE-2 study was conducted in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the COVID-19 Prevention Network (CoVPN).
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Eli Lillymehr Nachrichten
20.12.24 |
Eli Lilly given US approval to treat sleep disorder with weight-loss drug (Financial Times) | |
20.12.24 |
Schwacher Handel in New York: S&P 500 verliert zum Start des Freitagshandels (finanzen.at) | |
17.12.24 |
S&P 500-Wert Eli Lilly-Aktie: So viel Gewinn hätte ein Eli Lilly-Investment von vor 3 Jahren eingefahren (finanzen.at) | |
10.12.24 |
Eli Lilly stockt Dividende auf und plant massiven Aktienrückkauf - Aktie tiefer (dpa-AFX) | |
10.12.24 |
S&P 500-Wert Eli Lilly-Aktie: So viel Gewinn hätte ein Eli Lilly-Investment von vor einem Jahr eingefahren (finanzen.at) | |
06.12.24 |
MARKT USA/US-Arbeitsmarkt liefert Tendenz für die Wall Street (Dow Jones) | |
03.12.24 |
S&P 500-Titel Eli Lilly-Aktie: So viel hätte eine Investition in Eli Lilly von vor 10 Jahren abgeworfen (finanzen.at) | |
26.11.24 |
Handel in New York: S&P 500 letztendlich im Aufwind (finanzen.at) |
Analysen zu Eli Lillymehr Analysen
20.12.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
31.10.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
13.02.24 | Eli Lilly Buy | Jefferies & Company Inc. |